ESMO 2018 | Kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo

Thomas Powles

Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, London, UK, explains how this is an exciting time for kidney cancer, with data on the effects of an array of combinations now emerging. Prof. Powles discusses and compares avelumab/axitinib, pembrolizumab/axitinib, bevacizumab/atezolizumab, ipilimumab/nivolumab and more. Prof. Powles also explains the need to conduct further comparative studies between these drugs to drive decisions on how renal cell carcinoma patients should be treated. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video